TORONTO, May 12, 2023
/CNW/ - DRI Healthcare Trust (TSX: DHT.UN)
(TSX: DHT.U) ("DRI" or "the Trust") is pleased to
announce results of voting at its annual general meeting ("AGM") of
unitholders held on May 12, 2023. All
of the nominees for election as trustees of the Trust referred to
in its management information circular dated March 29, 2023 were elected to serve as trustees
for the ensuing year, and Deloitte LLP was reappointed as auditors
of the Trust.
Election of Trustees
Voting results for the election of each trustee were as
follows:
Trustee
|
Votes "for" as a
percentage
of votes cast for or
withheld for the trustee
|
Votes "withheld" as
a
percentage of votes cast
for or withheld for the trustee
|
Gary Collins
|
95.14 %
|
4.86 %
|
Ali Hedayat
|
96.30 %
|
3.70 %
|
Behzad
Khosrowshahi
|
99.75 %
|
0.25 %
|
Kevin Layden
|
96.30 %
|
3.70 %
|
Paul
Mussenden
|
91.68 %
|
8.32 %
|
Poonam Puri
|
95.12 %
|
4.88 %
|
Sandra
Stuart
|
99.79 %
|
0.21 %
|
Tamara
Vrooman
|
95.15 %
|
4.85 %
|
Appointment of Auditors
Unitholders also voted in favour of reappointing Deloitte LLP as
auditors of the Trust and authorizing the board of trustees to fix
their remuneration (96.32% in favour).
About DRI Healthcare
Trust
DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI
Capital"), the pioneer in global pharmaceutical royalty
monetization with a more than 30-year history of accelerating
innovation by providing capital to inventors, academic institutions
and biopharma companies. Since its founding in 1989, DRI Capital
has deployed more than US$2.5
billion, acquiring more than 70 royalties on 40-plus drugs,
including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara.
DRI Healthcare Trust's units are listed and traded on the Toronto
Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in
US dollars under the symbol "DHT.U". To learn more, visit
drihealthcare.com or follow us on LinkedIn.
SOURCE DRI Healthcare Trust